Reconstituted BPC-157 should generally be treated like other mixed peptide solutions: store at 2-8 C, label the mix date, avoid heat and repeated punctures, and plan around a roughly 28-day discard window unless the supplier provides narrower stability data
In highly concentrated samples, the biocompatible enhanced viscosity formulation comprises at least about 25%, at least about 35%, at least about 45%, at least about 55%, at least about 65%, at least about 75%, at least about 85%, at least about 90%, at least about 95%, or more by weight of the active agent
However, the increase of glutathione (GSH+GSSG and separate GSH and GSSG forms) during HR was more dynamic and stable
Ficlatuzumab is currently being tested in combination with cetuximab in a Phase Ib clinical trial of recurrent and metastatic HNSCC (NCT02277197)
Vitamin B12 deficiencies affect the way in which our bodies use valuable energy